Pharmacological inhibition of PARP offers protection during photoreceptor degeneration in retinitis pigmentosa [27,28], hypoxia-induced ischemic injury [19], hyperfusion-induced neurodegeneration [29] and diabetic retinal complication [30,31] in the retina. The gene discussed is PARP1; the disease is retinitis pigmentosa.